ClinicalTrials.gg
Active, not recruitingNCT05654142PIVOTUpdated Aug 31, 2026

The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older

An interventional study of Base intervention and Augmented Intervention in CARDIOMETABOLIC CONDITIONS, Obesity and Pre-diabetes, sponsored by University of Illinois at Chicago. Active, not recruiting at 3 sites in United States. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,029
Allocation
Randomized
Ages
50 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Obesity by University of Illinois at Chicago — 6 open to participants now, 8 under way, none of them phase 3. Obesity · University of Illinois at Chicago.

Enrollment
2nd of 33
1,029 · median 90
Started
2023
with 4 others
No phase
29 of 35
5 open now
Registered
29th of 35
by date

Among the 35 studies in Obesity by University of Illinois at Chicago, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2023, is one of 29 with no phase, and was the 29th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 35 studies in Obesity by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Obesity by University of Illinois at Chicago, or all of them as a file.
02

Study summary

This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.

Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.

Read the detailed description

This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.

English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with \<3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).

The investigators hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.

03

Conditions studied

  • CARDIOMETABOLIC CONDITIONS
  • Obesity
  • Pre-diabetes
  • Metabolic Syndrome
  • Type2diabetes
  • Hypertension
  • Dyslipidemias
04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 - 74 years (inclusive)
  • Confirmed (BMI) ≥27.0 based on:

    • Weight measured by participant at home using the study-provided wireless weight scale
    • Height documented in the EHR during at least 2 separate ambulatory care encounters within the past 2 years
  • Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia) in the EHR
  • Willing and able to accept randomization, and provide written and HIPAA authorization
  • Willing and able to participate in all aspects of the data collection and intervention protocols, including remote monitoring with a study-provided wireless weight scale and activity tracker and the use of a study tablet for access of MyChart, REDCap, and Fitbit apps

Exclusion criteria

Exclusion Criteria:

  • Unable to speak, read, understand English sufficiently for
  • No reliable Wi-Fi Internet access at home
  • Self-report of current active weight loss treatment, including research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS), other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) at the recruiting clinic or in the local community, and prescription weight loss medications
  • Screen positive for active eating disorder (bulimia nervosa or binge eating disorder) using PHQ- eating disorder module
  • Planned or prior bariatric surgery within the last 2 years (Note: patients who are more than 2 years post bariatric surgery can participate if otherwise eligible)
  • Unable to pass the Revised Physical Activity Readiness Questionnaire (PAR-Q) or obtain physician medical clearance to participate
  • Presence of any significant safety concerns or related to serious physical or mental health issues based on the EHR or self-report (e.g., type 1 diabetes or insulin dependence, myocardial infarction, stroke, cancer diagnosis (other than non-melanoma skin cancer) within the past 12 months and/or actively receiving cancer treatment, end-stage organ failure, bipolar disorder, psychosis, \<12 months)
  • Cognitive impairment based on the Callahan 6-item screener
  • Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)
  • Discontinued health care at the recruiting site, or plan to discontinue in the next 12 months
  • Participation in other behavioral, medical or surgical treatment studies by self-report that conflict with the primary weight loss outcome of this study.
  • Family/household member of an already enrolled participant or of a study team member
  • Investigator discretion for clinical safety or protocol adherence reasons
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
1,029 participants (actual)

Study arms

  • Active comparator
    Group A: Waitlist-Base Intervention

    Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52.

    Behavioral: Base intervention

  • Active comparator
    Group B: Waitlist-Augmented Intervention

    Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone.

    Behavioral: Augmented Intervention

  • Experimental
    Group C: Base Intervention (Responders)

    Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.

    Behavioral: Base intervention

  • Experimental
    Group D: Base Intervention (Non-responders)

    Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52.

    Behavioral: Base intervention

  • Experimental
    Group E: Augmented Intervention (Non-responders)

    Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52.

    Behavioral: Augmented Intervention

Interventions

  • BehavioralBase intervention

    12 Group Lifestyle Balance videos and digital motivational messages

  • BehavioralAugmented Intervention

    12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone

06

What researchers measure

Primary outcomes

  1. Assess change in weight from baseline to 52 weeks

    All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Assess change in weight from baseline to 12 weeks

    All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 12 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Baseline, 12 weeks,

  2. Assess trajectories of weight change from baseline to 6, 12, 24, and 52 weeks

    All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0), 6, 12, 24, and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks

  3. Assess changes in number of steps using Fitbit activity tracker at 6, 12, 24 and 52 weeks

    All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored number of steps using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  4. Assess changes in sleep metrics using Fitbit activity tracker at 6, 12, 24 and 52 weeks

    All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  5. Assess changes in physical activity using the International Physical Activity Questionnaire at 6, 12, 24 and 52 weeks

    All participants will self-administer the International Physical Activity Questionnaire (IPAQ), a 7-item questionnaire that captures a participant's physical activity over the last 7 days.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  6. Assess changes in fruit/veggie/fat/fiber intake at 6, 12, 24 and 52 weeks

    Dietary intake will be measured using 17-item fruit, vegetable, fat, and fiber screener by self-report. Correlations between screener estimates and estimated true intake were 0.5-0.8.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  7. Assess changes in efficacy in weight control at 6, 12, 24 and 52 weeks

    Participants will complete validated self-administered scale of self-efficacy for weight control using the Weight Efficacy Lifestyle Questionnaire. Sum of scores of 8 items, with a range between 0 and 80. Higher scores indicate higher self-efficacy to control eating behaviors.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  8. Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks

    Participants will complete validated self-administered scale of self-efficacy for dietary change using the Eating Habits Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher diet self-efficacy (i.e., higher ability to avoid eating certain unhealthy foods).

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  9. Assess changes in efficacy in physical activity at 6, 12, 24 and 52 weeks

    Participants will complete validated self-administered scale of self-efficacy for physical activity using the Exercise Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher exercise self-efficacy (i.e., greater confidence in performing certain behaviors consistently for at least 6 months).

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  10. Assess changes in social support/autonomous support per Health Care Climate Questionnaire at 6, 12, 24 and 52 weeks

    Participants will complete the Health Care Climate Questionnaire (HCCQ), which assessed their perceptions of the autonomy supportiveness of their care team. HCCQ contains 15 items, rated on a 5-point scale ranging from "not true at all" to "very true." After reversing the score of a negative item, an average score is calculated with higher score indicating a higher level of perceived autonomy support.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  11. Assess changes in problem solving ability at 6, 12, 24 and 52 weeks

    Participants' problem solving abilities will be assessed using the reliable and valid SPSI-R:S that contains 25 items in the following 5 subscales: positive problem orientation (PPO), negative problem orientation (NPO), rational problem solving (RPS), impulsive/careless style (ICS), and avoidance style (AS). Each item is rated on a 5-point scale ranging from "not at all true of me" (0) to "extremely true of me" (4). SPSI-R:S is a short version of the long SPSI-R:L form which has Cronbach's alpha coefficient of 0.95 for the total score and of 0.67-0.92 for subscales.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  12. Assess changes in patient activation at 6, 12, 24 and 52 weeks

    The 13-item PAM measures patient's self-reported knowledge, skill, and confidence for self-managing his or her health condition. It demonstrated acceptable internal consistency (Conbrach's alpha = 0.81). The 13-item PAM score accounts for 92% of the variation in the activity measured by the original 22-item PAM. The score is also significantly correlated with general preventive behaviors and disease-specific self-management behaviors.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  13. Assess changes in perceived stress at 6, 12, 24 and 52 weeks

    Perceived Stress Scale (PSS) measures the perception of stress (i.e., the degree to which situations in one's life are appraised as stressful). PSS contains 14 items, rated on a 5-point scale ranging from "never" to "very often." After reversing the scores on 7 positive items, a sum of score is calculated with higher score indicating higher perceived stress. Cronbach's alpha ranged from 0.84 to 0.86.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  14. Assess changes in sleep disturbance score at 6, 12, 24 and 52 weeks

    Sleep disturbance is assessed on the 8-item PROMIS sleep disturbance scale short form which measures symptoms of insomnia. Each item is scaled from 1 (not at all) to 5 (very much). Sleep disturbance score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep disturbance.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  15. Assess changes in sleep impairment score at 6, 12, 24 and 52 weeks

    Sleep impairment is assessed on the 8-item PROMIS sleep-related impairment scale short form which measures symptoms of daytime sleepiness. Each item is scaled from 1 (not at all) to 5 (very much). Sleep impairment score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep impairment.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  16. Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks

    Cognitive functioning will be assessed on the PROMIS version 1.0 short-form subscales of Cognitive Abilities and Cognitive Concerns. Each subscale contains 8 items. The Cognitive Abilities items target positive self-assessments of cognitive functioning such as "My memory has been as good as usual" and "I have been able to concentrate." The Cognitive Concerns items are worded negatively and express concerns in the same areas, for examples, "My thinking has been slow" and "I have had trouble shifting back and forth between different activities that require thinking." Items on both subscales use a 5-point rating from "not at all" to "very much." Items are summed to create a total score for each subscale.

    Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks

  17. Assess changes in cardiovascular risk at 52 weeks

    The non-laboratory Framingham risk prediction model estimates individuals' 10-year risk of developing any major atherosclerotic cardiovascular disease (CVD) event. The component risk factors are age, BMI, systolic blood pressure, smoking status, presence of diabetes, and medication for high blood pressure. Participants will be asked to confirm their age and report their smoking history at baseline and current smoking status at baseline and 52 weeks. The BMI will be calculated based on participants' self-measured weight data as described above and height measurements abstracted from their EHR. Blood pressure, diagnosis of diabetes, and prescriptions for high blood pressures will also be abstracted from the EHR.

    Time frame: Baseline, 52 weeks

  18. Assess changes in number/severity of comorbidity at 52 weeks

    The Cumulative Illness Rating Scale (CIRS) is a composite index of the number and severity of medical problems by organ system. It has been validated in diverse populations and settings, including primary care patients, with published guidelines and electronic tools for application and scoring using electronic health record (EHR) data.

    Time frame: Baseline, 52 weeks

  19. GLB videos viewed

    GLB videos viewed will be automatically tracked.

    Time frame: Throughout the intervention, up to 1 year

  20. PST coaching sessions completed

    PST coaching sessions completed will be recorded by coach in REDCap.

    Time frame: Throughout the intervention, up to 1 year

  21. Self-monitoring of weight

    All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). Participants will be encouraged to weigh themselves at least 3 days a week throughout the study. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible) at consistent time. They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Through study completion, an average of 1 year

  22. Self-monitoring of activity & sleep

    All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. Participants will be encouraged to wear their activity tracker for at least 10 hours on 3 or more days a week throughout the study. The investigators will obtain participants' self-monitored number of steps and sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.

    Time frame: Through study completion, an average of 1 year

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 44 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2022
First posted
Dec 16, 2022
StartActual
Apr 17, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05654142
Responsible party
Jun Ma (MD, PhD, Principal Investigator, Beth and George Vitoux Professor of Medicine, University of Illinois at Chicago) — Principal investigator
First posted
Dec 16, 2022
Start date
Apr 17, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion